| Patient | Frances Burney |
|---|---|
| Date of birth | 1967-06-13 |
| Identifiers | MRN HR-EN013-SYN; SSN (made up) 000-13-9108 |
| Document date | 2026-10-19 |
| Author | Harriet Pell, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Review three weeks after right mastectomy. [S]
Mrs. Burney returns three weeks after a right total mastectomy with sentinel node biopsy. The breast MRI before surgery showed a second 0.8 cm cancer at 7 o'clock, confirmed by MRI-guided biopsy, so with Dr. Marsh she chose mastectomy; she did not want reconstruction. The germline panel showed no pathogenic variant. She had general anesthesia with a pectoral nerve block, was told of each step beforehand, and went home the next morning. Her pain was 2 out of 10 by the third day; she needed no opioid at home and stopped acetaminophen at two weeks. A seroma after drain removal was aspirated once by the surgical team eleven days ago and has not returned. The pathology shows multicentric invasive ductal carcinoma, 2.6 cm and 0.8 cm, grade 2, with clear margins and 0 of 3 sentinel nodes involved. The recurrence score is 13. Dr. Marsh and the breast program's medical oncologist advise five years of anastrozole, with no chemotherapy and no radiation. She has a little numbness under the right arm and is doing her shoulder exercises. Her bone density scan this morning shows low bone mass. [S]
| Element | Detail |
|---|---|
| Interval change | Right total mastectomy and sentinel node biopsy three weeks ago; seroma aspirated once |
| Pathology | pT2(m) pN0(sn), grade 2, margins clear; recurrence score 13 |
| Genetics | No pathogenic germline variant |
| Pain | None at rest; no analgesics now |
| Function | Shoulder flexion improving; walking daily |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | No fever; energy returning |
| Integumentary | Negative | Wound healed; no fluid under the flap |
| Musculoskeletal | Positive | Mild tightness raising the right arm; no bone or joint pain |
| Neurological | Positive | Small patch of numbness under the right arm |
| Genitourinary | Negative | No vaginal dryness or bleeding |
| Psychiatric | Negative | Relieved and sleeping well; PHQ-2 score 1 |
6 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Acetaminophen 500 mg oral tablet, two tablets (1000 mg) by mouth every 6 hours for pain after surgery, no more than 3000 mg a day | Two tablets every 6 hours | Oral route | 2026-09-30 to 2026-10-14 | completed | S |
| Ibuprofen 400 mg oral tablet, one tablet by mouth every 8 hours with food for five days after surgery | One tablet every 8 hours with food | Oral route | 2026-09-30 to 2026-10-05 | completed | S |
| Anastrozole 1 mg oral tablet, one tablet by mouth once daily, planned for five years | One tablet once daily | Oral route | 2026-10-19 | active | S |
| Cholecalciferol (vitamin D3) 1000 units oral tablet, one tablet by mouth once daily | One tablet once daily | Oral route | 2026-10-19 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-10-19 | Body height | 160 | cm | S |
| 2026-10-19 | Body weight | 60.9 | kg | S |
| 2026-10-19 | Body mass index (BMI) [Ratio] | 23.8 | kg/m2 | S |
| 2026-10-19 | Systolic blood pressure | 122 | mm[Hg] | S |
| 2026-10-19 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 2026-10-19 | Heart rate | 74 | /min | S |
| 2026-10-19 | Respiratory rate | 14 | /min | S |
| 2026-10-19 | Body temperature | 36.6 | Cel | S |
| 2026-10-19 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-10-19 | Cholesterol [Mass/volume] in Serum or Plasma | 214 | mg/dL | <=199 mg/dL | High | S |
| 2026-10-19 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 58 | mg/dL | >=50 mg/dL | Normal | S |
| 2026-10-19 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 132 | mg/dL | <=99 mg/dL | High | S |
| 2026-10-19 | Triglyceride [Mass/volume] in Serum or Plasma | 120 | mg/dL | <=149 mg/dL | Normal | S |
| 2026-10-19 | 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma | 24 | ng/mL | 30-100 ng/mL | Low | S |
| 2026-10-19 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 1 | {score} | S | ||
| 2026-10-19 | DXA Lumbar spine [T-score] Bone density | -1.4 | {T-score} | >=-1 | Low | S |
| 2026-10-19 | DXA Femur [T-score] Bone density | -1.7 | {T-score} | >=-1 | Low | S |
Vital signs recorded on 2026-10-19; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well, cheerful |
| Chest wall | Right mastectomy scar healed; flap flat with no fluid; no erythema |
| Lymph nodes | No axillary or supraclavicular nodes; left breast without masses |
| Extremities | Arm circumference 26.0 cm on each side 10 cm above the elbow; right shoulder flexion 150 degrees, abduction 140 degrees |
| Musculoskeletal | No spinal tenderness; joints without swelling (baseline before anastrozole) |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Invasive ductal carcinoma of the right breast, upper outer quadrant at 10 o'clock, presenting as a firm lump after about a year of breast ache; core biopsy: grade 2, estrogen and progesterone receptor positive, HER2 negative; clinical stage T2 N0 (cT2 cN0 M0); synthetic modern diagnosis linked to the documented 1811 breast disease and mastectomy, whose cancer diagnosis is debated | active | confirmed | C50.411 | S — Synthetic diagnosis confirmed by biopsy and surgical pathology in the modern episode; whether her historical disease was cancer remains a retrospective interpretation (R). |
| Estrogen receptor positive status of the breast cancer (ER 95 percent, PR 70 percent) | active | confirmed | Z17.0 | S — Synthetic receptor result; no tissue from her lifetime was examined. |
| Absence of the right breast after total mastectomy without reconstruction, her choice | active | confirmed | Z90.11 | S — Synthetic coding of the modern mastectomy, which echoes the documented operation. |
| Long-term use of anastrozole as adjuvant endocrine therapy | active | confirmed | Z79.811 | S — Synthetic treatment status. |
| Low bone mass (osteopenia) on baseline DXA before anastrozole: lumbar spine T-score -1.4, femoral neck -1.7; 10-year major osteoporotic fracture risk about 8 percent (FRAX); vitamin D insufficiency | active | confirmed | M85.80 | S — Synthetic finding on the baseline DXA the protocol requires for an aromatase inhibitor. |
| Seroma under the right mastectomy flap after drain removal, without infection; aspirated once by the breast surgery team; resolved | resolved | confirmed | L76.34 | S — Synthetic common complication of the synthetic mastectomy; it does not echo a documented illness. |
| Firm lump in the upper outer quadrant of the right breast after about a year of heavy breast ache; clinically suspicious, imaging and biopsy booked | resolved | confirmed | N63.11 | S — Synthetic presenting concern at the index visit, superseded by the biopsy diagnosis; the year of breast ache echoes her documented account (D). |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Cancer-related history and physical examination | Every 3 to 6 months for the first 3 years | Completed today | Wound healed; no signs of recurrence |
| Laboratory | Surgical pathology and recurrence score | After surgery | Up to date | pT2(m) pN0(sn), margins clear; recurrence score 13 |
| Medication safety | Aromatase inhibitor start | At initiation | Completed today | Anastrozole 1 mg daily started; postmenopausal for eight years, so no ovarian suppression needed |
| Imaging | Bone density (DXA) | Baseline at aromatase inhibitor start, then every 2 years | Completed today | Lumbar spine T-score -1.4, femoral neck -1.7: low bone mass |
| Laboratory | Lipid panel | Periodically on an aromatase inhibitor, by cardiovascular risk | Completed today | Total cholesterol 214, HDL 58, LDL 132, triglycerides 120 mg/dL |
| Laboratory | Calcium and vitamin D adequacy | Ongoing on an aromatase inhibitor | Completed today | 25-hydroxyvitamin D 24 ng/mL, insufficient; vitamin D3 started and calcium from food advised |
| Medication safety | Bone-modifying agent (bisphosphonate or denosumab) | When fracture risk is high, or as adjuvant therapy at higher recurrence risk | Not indicated | Fracture risk about 8 percent and low recurrence risk |
| Examination | Aromatase inhibitor joint pain and musculoskeletal review | Every visit | Completed today | Baseline: no joint pain |
| Survey | Vasomotor and vaginal symptoms | Periodically on endocrine therapy | Completed today | Baseline: none |
| Examination | Lymphedema assessment and risk-reduction counseling | Every visit | Completed today | Arm circumference 26.0 cm on each side; no swelling; counseled on early signs |
| Examination | Lymphedema baseline arm measurements before surgery | Before axillary surgery | Deferred | Not measured at the pre-anesthesia visit as planned, a deviation from the protocol. Today's measurements are equal on both sides, so no swelling has been missed; they serve as the baseline, and arm measurement has been added to the pre-operative checklist |
| Referral | Physical therapy for shoulder movement | After axillary surgery when movement is limited | Referred | Shoulder flexion 150 degrees; four sessions requested |
| Survey | Depression screen (PHQ-2) | At periodic intervals | Completed today | PHQ-2 score 1 |
| Laboratory | Routine blood counts, chemistry, liver tests, and tumor markers | Not recommended in asymptomatic stage I to III survivors | Not indicated | None ordered |
| Imaging | CT, bone scan, or PET for distant spread | Not recommended in asymptomatic survivors | Not indicated | No symptoms |
| Imaging | Diagnostic mammogram of the left breast | Yearly after mastectomy | Due | In August, one year after the diagnostic mammogram |
| Referral | Radiation oncology | After mastectomy when nodes are positive or margins are close | Not indicated | Node-negative with clear margins |
| Imaging | Echocardiogram (LVEF) | During and after trastuzumab | Not indicated | No trastuzumab or anthracycline |
| Self-management | Survivorship care plan and lifestyle counseling | Within one year of treatment; lifestyle every visit | Completed today | Written plan given; 150 minutes of activity a week, strength exercise twice a week once allowed, alcohol at or below one drink a day |
Goal progress:
Guideline basis: NCCN Clinical Practice Guidelines in Oncology: Breast Cancer, Version 5.2025 (2025); American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline. CA Cancer J Clin 2016;66(1):43-73 (2016); Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update (2019); CMID: Clinical Monitoring Intelligence Database, breast cancer monograph (2026)
Follow-up: Physical therapy for the shoulder. Adult preventive visit next week. Survivorship visit in three months. Next scheduled visit 2026-10-29: adult preventive visit. [S]